Long-term safety and efficacy of budesonide nasal aerosol in perennial rhinitis. A 12-month multicentre study.

摘要: A long-term safety study of intranasally administered budesonide, a topical glucocorticoid, has been performed. 104 patients with perennial rhinitis, allergic or non-allergic, participated in multicentre seven ENT-clinics utilising an identical protocol. budesonide dosage 400 μg/day was used as starting dose, but the were at liberty to reduce daily dose 200 μg. The observed intervals up 12 months. At entry and follow-up visits following parameters recorded: rhinoscopic findings, nasal symptom scores, blood chemistry, hematology, urinalysis determination plasma cortisol levels before after stimulation ACTH (Synacthen®). Nasal biopsies taken from 50 beginning completion examined blinded way by indepndent pathologist. analysis revealed no histopathological changes mucosa. rhinoscopy signs atrophy Candida reported. Lividity mucosa significantly reduced during trial, which also case for congestion secretion. All assessed baseline period. No clinically significant hematological chemistry observed. Plasma challenge influence on hypothalamic pituitary adrenal axis. tachyphylaxis observed; contrary, there clear tendency reduction necessary keep symptom-free. present suggests that intransal is safe valuable addition our therapeutic armory rhinitis.